REFERENCES
- Aus G, Bergdahl S, Hugosson J, Norlén L. Transrectal ultrasound (TRUS) volume determinations of the whole prostate and the adenomas separately in patients with clinically benign prostatic hyperplasia: Correlation to resected weight, blood loss and duration of operation. Br J Urol 1994; 73: 659–663.
- Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: Correlation and clinical application. J Clin Lab Anal 1990; 4: 135–137.
- Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817–821.
- Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815–816.
- Clements R, Etherington RJ, Griffiths GJ, Peeling WB, Hughes H, Penney MD. Inter-relation between measurement of serum prostatic specific antigen and transrectal ultrasound in the diagnosis of benign prostatic hyperplasia and prostatic cancer. Br J Urol 1992; 70: 183–187.
- Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M. Relationship between prostate specific antigen and age in the benign prostate. Br J Urol 1993; 71: 445–450.
- Coplen DE, Andriole GL, Yuan JJJ, Catalona WJ. The ability of systemic transrectal ultrasound guided biopsy to detect prostate cancer in men with clinical diagnosis of benign prostatic hyperplasia. J Urol 1991; 146: 75–77.
- Levine AC, Droller MA, Kirschenbaum A, Gabrilove JL, Kaplan P. Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide. Urology 1989; 34: 10–13.
- Littrup PJ, Kane RA, Williams CR, et al. Determination of prostate volume with transrectal US for cancer screening. Part 1: Comparison with prostate-specific antigen assays. Radiology 1991; 178: 537–542.
- Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–923.
- Oesterling JE, Jacobsen SJ, Chute CG, et al. The establishment of age-specific reference ranges for prostate-specific antigen. J Urol 1993; 149: 510A.
- Papsidero LD, Kurlyama M, Wang MC, et al. Prostate antigen: A marker for human prostate epithelial cells. J Natl Cancer Inst 1981; 66: 37–42.
- Partin AW, Carter HB, Chan DW, et al. Prostate-specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747–752.
- Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 1088–1090.
- Terris MK, Freiha FS, McNeal JE, Stamey TA. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 1991; 146: 78–84.
- Veneziano S, Pavlica P, Querzé R, Nanni G, Lalanne MG, Vecchi F. Correlation between prostate specific antigen and prostate volume, evaluated by transrectal ultrasonography: Usefulness in diagnosis of prostate cancer. Eur Urol 1990; 18: 112–116.
- Vesey SG, Goble M, Ferro MA, Stower MJ, Hammonds JC, Smith PJB. Quantification of prostatic cancer metastatic disease using prostate specific antigen. Urology 1990; 35: 483–486.
- Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–163.
- Weber JP, Oesterling JE, Peters CR, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987–992.